Regemat 3D
Regemat 3D is a Spanish biomedical company that sells an integrated 3D bioprinting and bioreactor platform for regenerative medicine research. It serves academic, government, and healthcare laboratories in 35+ countries with customizable bioprinters, the patented BMAP® Knee Bioreactor, proprietary bioinks, software, and training services.
- Company typePrivate
- Founded2015
- HeadquartersArmilla, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Regemat 3D does
Regemat 3D (legal entity REGEMAT 3D S.L.) is a privately held Spanish biomedical technology company founded in 2015 and headquartered in Armilla (Granada), Spain, with a team in the 11–50 range. It develops and sells an integrated tissue engineering platform that pairs 3D bioprinting hardware with bioreactor systems, biomaterials, and software, positioning itself as the only vendor offering an end-to-end workflow that takes printed constructs from scaffold to functional living tissue rather than stopping at scaffold fabrication.
The core product portfolio includes the BIO V1 and REG4Life modular bioprinters, the patented BMAP® Knee Bioreactor (the only commercial bioreactor specifically designed for cartilage tissue maturation and osteochondral regeneration), the GelMA-Graphene Kit (an electroconductive bioink co-developed with Graphenano and Tessenderlo Group), R3D Studio bioprinting software, and a Virtual Reality Training Platform described as the first of its kind for 3D bioprinting. Supporting revenue lines span photoinitiators and other reagents, hydrogels, thermoplastics, consumables, and a portfolio of protocols via LabMethods.org. The customer base is concentrated in academic and government research institutions (e.g., University of Erlangen-Nuremberg, National Eye Institute, University of Iowa, Politecnico di Torino, several Spanish universities), with secondary exposure to healthcare/medical and pharmaceutical customers pursuing drug-delivery and personalized medicine use cases.
The business model is enterprise hardware-led with a hybrid GTM: direct field sales through business developers for major equipment purchases (quote-based, no public pricing), regional distribution partnerships covering Spain (Palex), Italy (Schaefer SEE), the CEE region (SEQme), and Egypt/MENA (MiraLab), plus a self-serve e-commerce storefront for reagents and consumables. Revenue is also supplemented by recurring software licensing, intensive training courses (e.g., 35-hour 3D Bioprinting & Cell Culture Course), and turnkey lab setup services. The company has executed two Crowdcube funding rounds totaling approximately $1.1M (2020 and 2022), received a Torres Quevedo fellowship from the Spanish State Research Agency in 2024, and participates in EU-funded consortia (REBORN Project, inkjet-bioAM Project); revenue and valuation are not publicly disclosed.
Regemat 3D firmographics
Firmographics- Name
- Regemat 3D
- Legal name
- REGEMAT 3D S.L.
- Website
- https://regemat3d.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Regemat 3D is a Spanish biomedical company that sells an integrated 3D bioprinting and bioreactor platform for regenerative medicine research. It serves academic, government, and healthcare laboratories in 35+ countries with customizable bioprinters, the patented BMAP® Knee Bioreactor, proprietary bioinks, software, and training services.
- Ownership category
- akta.pro rank
Regemat 3D industry classification
Industry- Product category
- 3D Bioprinting and Tissue Engineering Equipment
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
- akta.pro secondary industries
- 3D Bioprinting & Biofabrication (HLAAAGAC), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where Regemat 3D is headquartered
LocationHeadquarters
- HQ city
- Armilla
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Regemat 3D business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- 3D Bioprinters: Sale of modular bioprinters (BioV1, REG4Life) designed for research and biofabrication applications. Fully customizable systems targeting research institutions and companies.
- Bioreactors: Sale of specialized bioreactors including the patented BMAP® Knee Bioreactor for cartilage tissue maturation. Premium-priced specialized equipment.
- Bioinks and Biomaterials: Sale of specialized bioinks including the GelMA-Graphene Kit, hydrogels, thermoplastics, and polymerization initiators.
- Reagents and Consumables: Photoinitiators (LAP, IRGACURE 2959, RU(BPY)3), cell culture reagents, dispensing tips, syringe barrels, pistons, and connectors.
- Software Licenses: Sale of R3D Studio bioprinting software with advanced design and visualization capabilities.
- Training and Services: Onsite courses (3D Bioprinting & Cell Culture, 35-hour intensive programs), turnkey lab setup services, and technical support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Enterprise/B2B hardware and software solutions |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels7 records
Regemat 3D product offering
Product offeringCore offering
REGEMAT 3D designs, manufactures, and sells modular 3D bioprinters (BioV1, REG4Life), the patented BMAP® Knee Bioreactor for cartilage tissue maturation, bioprinting software (R3D Studio) and a VR Training Platform, alongside biomaterials (GelMA-Graphene bioink), reagents (LAP, IRGACURE 2959, RU(BPY)3), consumables, training courses, and turnkey biofabrication laboratory setup services for regenerative medicine researchers.
Product overview
Regemat 3D offers an integrated tissue engineering platform combining hardware, software, biomaterials, and services. The core portfolio includes two 3D bioprinters (BIO V1 and REG4Life), the patented BMAP® Knee Bioreactor for cartilage maturation, R3D Studio software for design and control, and a VR Training Platform for immersive learning. Supporting products include a range of reagents (photoinitiators LAP, IRGACURE 2959, RU(BPY)3; crosslinker Calcium Chloride; assay kits), consumables (dispensing tips, syringes), and the GelMA-Graphene electroconductive bioink. Services encompass training courses and turnkey lab setup. The platform enables end-to-end tissue engineering from scaffold printing through tissue maturation.
Differentiator
Problem solved
Functional benefit
Products and services
- BIO V1 Bioprinter A modular 3D bioprinter designed for advanced research and biofabrication, compatible with a wide range of biomaterials, printing surfaces, and extrusion technologies. Targeted at tissue engineering and regenerative medicine researchers.
- REG4Life Bioprinter A fully customizable 3D bioprinter for advanced research with adaptable extrusion systems, temperature settings, and other key parameters to meet specific research requirements. Targeted at laboratories needing tailored biofabrication capabilities.
- BMAP® Knee Bioreactor The only patented bioreactor system specifically designed for osteochondral regeneration. Replicates physiological conditions of the human knee, applies controlled movements to transform 3D-printed scaffolds into functional cartilage tissue. Targeted at clinical tissue engineering and cartilage regeneration research.
- R3D Studio Software Next-generation bioprinting software for the tissue engineering and regenerative medicine community. Features intuitive interface, advanced scaffold customization, enhanced visualization with trajectory preview, and seamless STL/G-code file handling.
- VR Training Platform for 3D Bioprinting First Virtual Reality training platform specifically developed for 3D bioprinting. Provides step-by-step interactive training across protocols including 3D bioprinting, bioink preparation, and 3D cell culture techniques.
- GelMA-Graphene Kit The only electroconductive bioink based on GelMA for advanced tissue engineering applications. Co-developed with Graphenano and Tessenderlo Group. Features customizable GelMA, LAP, and graphene concentrations for adapting mechanical and biological properties to specific tissues.
- GelMA-Graphene Hydrogel World's only GelMA-Graphene hydrogel. Revolutionary electroconductive bioink developed for next-generation tissue engineering applications, validated by leading Spanish universities.
- LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) Water-soluble, cytocompatible photoinitiator ideal for crosslinking methacrylated hydrogels in 3D bioprinting and tissue engineering. Activated at 365 nm and 405 nm for faster polymerization with improved cell viability.
- IRGACURE 2959 High-purity UV photoinitiator optimized for crosslinking methacrylated hydrogels (GelMA, HumaDerMA®, OsteoGelMA®) in 3D bioprinting and tissue engineering. Activated at 365 nm.
- RU(BPY)3 and SPS Visible light-activated photoinitiator (≥400 nm, optimal at 450 nm) for gentle crosslinking of biomaterials like GelMA, collagen, and silk fibroin, ensuring high cell viability.
- Calcium Chloride (CaCl₂) High-purity ionic crosslinker essential for rapid gelation of alginate-based bioinks in 3D bioprinting and tissue engineering. Enables stable hydrogel formation.
- Cyto3D Live-Dead Assay Kit Versatile assay to determine live/dead nucleated cells using a quick one-step staining procedure with Acridine orange (AO) and Propidium Iodide (PI) for dual-fluorescence analysis.
- VitroGel® Organoid Recovery Solution Non-enzymatic cell harvesting solution for recovering cells/organoids from hydrogel or animal-based ECM. Less than 15-minute cell recovery protocol.
- Dispensing Tips Dispensing tips ensuring accurate and controlled bioink extrusion. Available in polypropylene (conical) and stainless steel (straight) designs for clog-free printing.
- 3D Bioprinting & Cell Culture Course Intensive onsite 35-hour course offering theoretical and practical sessions in biofabrication, biomaterials, and tissue engineering. Includes hands-on lab sessions and technology demonstrations for researchers and professionals.
- Turnkey Lab Service Fully equipped lab setup and technical support services for establishing biofabrication laboratories, including continuous technical assistance.
Quantifiable outcome
- Functional cartilage tissue maturation in weeks through bioreactor stimulation
- +1 more outcomes
Companies that use Regemat 3D
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Regemat 3D technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Regemat 3D partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered strategic, core, flagship and support.
- MSA University CairostrategicStrategic visit to Egypt to engage with key academic and scientific institutions. Discussions on future of 3D bioprinting and biotechnology in the region. Part of MENA expansion strategy.
- inkjet-bioAM Project ConsortiumstrategicEU-funded project consortium including PROFACTOR, Research Center Pharmaceutical Engineering GmbH, University of Graz, Tiger Coatings, Infineon Technologies, and 8 other partners. REGEMAT 3D hosted the General Meeting welcoming 22 experts from five countries.
- Universidad de MurciastrategicDr. María José López Andreo from Universidad de Murcia visited REGEMAT 3D's Biofabrication Laboratory to explore 3D bioprinting technologies and gain hands-on experience with advanced biofabrication tools.
- LeartikerstrategicCollaborative research initiative focused on developing a 3D bioprinted in vitro cartilage model using mesenchymal stem cells (MSCs) and promoting their differentiation into chondrocytes. Hosted Izar Gorroñogoitia at REGEMAT 3D's Biofabrication Laboratory.
- Schaefer SEE SrlcoreDistribution agreement for Italy. Schaefer SEE Srl is an official distributor of REGEMAT 3D products, hosting hands-on workshops and providing local support. Representatives participated in REGEMAT 3D's 3D Bioprinting & Cell Culture Course.
- SEQme s.r.o.coreDistribution agreement extending coverage to Poland, Czech Republic, and Slovakia. Both SEQme representatives participated in REGEMAT 3D's training course, demonstrating commitment to biofabrication solutions.
- REBORN Project ConsortiumflagshipEuropean research consortium focused on advancing biofabrication. REGEMAT 3D participated in M18 review meeting in Porto hosted by Universidade do Porto and i3S-Instituto de Investigação e Inovação em Saúde. CEO attended General Assembly in Berlin (January 2025).
- Palex EspañacoreExclusive distributor in Spain. Supported REGEMAT 3D's participation in III Congreso de Investigación PTS Granada, one of Spain's premier biomedical events.
- University of Erlangen-Nuremberg (Institute of Biomaterials)coreCollaboration with Prof. Aldo R. Boccaccini and Dr. Rainer Detsch for hosting biofabrication workshop. The workshop demonstrated REGEMAT 3D's bioprinters, bioreactors, and VR training platform to researchers and faculty.
- GraphenanoflagshipCo-development partner for the GelMA-Graphene Kit, the world's only electroconductive GelMA-based bioink. Graphenano contributed graphene technology for advanced tissue engineering applications.
- Tessenderlo GroupflagshipCo-development partner for the GelMA-Graphene Kit, contributing to the unique electroconductive bioink formulation for tissue engineering.
- MiraLab (Lab Equipment)coreLocal distributor in Egypt alongside the MSA University visit, supporting regional expansion in the MENA market.
- University of IowastrategicResearch collaboration on multimaterial synthetic bone grafts using REGEMAT 3D bioprinter. Publication describes development of gelatin-coated, 3D-printed PCL scaffolds for enhanced bone defect regeneration through sustained delivery of miR-200c.
- Universidad de SevillastrategicResearch team led by Gloria Mora Castaño used REGEMAT 3D's BioV1 bioprinter to develop 3D printed gastroretentive floating tablets for controlled drug release. Collaboration with An Najah National University and Ghent University.
- National Eye Institute (NEI)strategicScientists at NEI successfully 3D bioprinted functional eye tissue, marking transformative advancement in regenerative medicine and vision restoration using REGEMAT 3D technologies.
- University of GranadastrategicValidation partner for GelMA-Graphene hydrogel. Prof. Juan Antonio Marchal from University of Granada collaborates on research and presented at PTS Granada Congress.
- University of BarcelonastrategicValidation partner for the GelMA-Graphene hydrogel alongside University of Granada and University of Alcalá.
- University of AlcalástrategicValidation partner for the GelMA-Graphene hydrogel alongside University of Granada and University of Barcelona.
- OnGranada Tech CitysupportLocal innovation cluster providing support to REGEMAT 3D as part of the inkjet-bioAM project and broader regional ecosystem development.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Regemat 3D competitors and assessment
Company assessmentDirect peers
- 3D Biotek: 3D Biotek develops 3D bioprinting and tissue engineering technologies, including scaffolds and bioprinters for research applications. Comparable niche player to Regemat 3D in product portfolio and academic customer base.
- CELLINK (BICO): CELLINK, now part of BICO, is one of the leading commercial suppliers of 3D bioprinters, bioinks, and consumables for regenerative medicine research. Directly comparable to Regemat 3D in target customers (research institutions), product portfolio (bioprinters + bioinks), and business model (hardware + consumables), but operates at substantially greater scale.
- Allevi (3D Systems): Allevi, acquired by 3D Systems, develops desktop 3D bioprinters and bioinks widely used in academic tissue engineering labs. Competes head-to-head with Regemat's BioV1 and REG4Life systems in the same research institution buyer segment.
- Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting platforms for tissue engineering and regenerative medicine, with a focus on therapeutic applications. Comparable to Regemat 3D in mission (creating functional living tissues) and target market (research and pharma/biotech), though differentiated technology.
- RegenHU: RegenHU is a Swiss manufacturer of modular 3D bioprinters and bioinks for tissue engineering and regenerative medicine research. Highly comparable to Regemat 3D in product type (modular bioprinters), customer segment (academic and pharma research), and emphasis on customization.
- Poietis: Poietis is a French biotechnology company specializing in laser-assisted 3D bioprinting for tissue engineering. Direct peer in the bioprinting hardware space serving similar regenerative medicine research customers in Europe.
- Organovo: Organovo is a pioneer in 3D bioprinting of functional human tissues for therapeutic and research applications. Comparable to Regemat 3D in tissue engineering focus, though Organovo is more drug-discovery oriented and has undergone significant restructuring.
- Brinter: Brinter is a Finnish 3D bioprinter company offering modular bioprinting systems for tissue engineering and pharmaceutical research. Comparable in product positioning (modular multi-material bioprinters) and customer base, but a regional European peer.
Regional players
- GeSiM (Gesellschaft für Silizium-Mikrosysteme): GeSiM is a German manufacturer of specialized 3D bioprinters and micro-dosing systems for life science research. Comparable to Regemat 3D in product type (modular bioprinters for research), with strong overlap in European academic customer base though based in Germany rather than Spain.
Broad incumbents
- Stratasys: Stratasys is a global leader in 3D printing with biomedical applications including research-grade printing solutions. A broad incumbent in 3D printing that overlaps with Regemat 3D's research customer base, though Stratasys is not specialized in bioprinting/living tissue fabrication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Regemat 3D social profiles
Digital presenceRegemat 3D financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regemat 3D leadership team
Management profileNumber of profiles
Profiles8 records
Regemat 3D funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regemat 3D M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regemat 3D
What does Regemat 3D do?
REGEMAT 3D designs, manufactures, and sells modular 3D bioprinters (BioV1, REG4Life), the patented BMAP® Knee Bioreactor for cartilage tissue maturation, bioprinting software (R3D Studio) and a VR Training Platform, alongside biomaterials (GelMA-Graphene bioink), reagents (LAP, IRGACURE 2959, RU(BPY)3), consumables, training courses, and turnkey biofabrication laboratory setup services for regenerative medicine researchers.
Is Regemat 3D a public or private company?
Regemat 3D is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Regemat 3D founded?
Regemat 3D was founded in 2015. It employs 11 to 50 people.
Where is Regemat 3D based?
Regemat 3D is headquartered in Armilla, Spain, in the Europe region.
How does Regemat 3D make money?
Six revenue lines are on record. 3D Bioprinters are the primary driver. The others are bioreactors, bioinks and Biomaterials, reagents and Consumables, software Licenses and training and Services.
Who are Regemat 3D's main competitors?
Direct peers on record are 3D Biotek, CELLINK (BICO), Allevi (3D Systems), Aspect Biosystems, RegenHU, Poietis, Organovo and Brinter. GeSiM (Gesellschaft für Silizium-Mikrosysteme) is listed as a regional player. Stratasys is listed as a broad incumbent.
Does Regemat 3D have an API?
No public API is recorded for Regemat 3D.
What industry is Regemat 3D in?
Regemat 3D's product category is 3D Bioprinting and Tissue Engineering Equipment. Its primary akta.pro industry code is IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware), with a secondary code of HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 541714 and its SIC code is 3841.